Daily Anesthesiology Research Analysis
Three high-impact studies advance anesthesiology and perioperative science: (1) glutamatergic neurons in the supramammillary nucleus causally regulate loss and return of consciousness under propofol anesthesia in mice; (2) a metabolite local anesthetic, 2',6'-pipecoloxylidide (PPX), achieves sensory-selective peripheral and neuraxial blockade with favorable safety in rodents; and (3) a controlled human endotoxemia trial shows short-stored platelets outperform long-stored platelets during inflamm
Summary
Three high-impact studies advance anesthesiology and perioperative science: (1) glutamatergic neurons in the supramammillary nucleus causally regulate loss and return of consciousness under propofol anesthesia in mice; (2) a metabolite local anesthetic, 2',6'-pipecoloxylidide (PPX), achieves sensory-selective peripheral and neuraxial blockade with favorable safety in rodents; and (3) a controlled human endotoxemia trial shows short-stored platelets outperform long-stored platelets during inflammation, informing transfusion strategy.
Research Themes
- Neural circuit mechanisms of anesthesia consciousness transitions
- Sensory-selective local anesthetics for motor-sparing analgesia
- Transfusion medicine: platelet storage effects during inflammation
Selected Articles
1. Role of Supramammillary Nucleus Glutamatergic Neurons in Modulating Consciousness Transitions during Propofol Anesthesia in Mice.
Using photometry, chemogenetics, and optogenetics in mice, the authors show that supramammillary glutamatergic neurons decrease activity before propofol-induced loss of consciousness and surge at recovery. Manipulating these neurons bidirectionally altered induction and emergence times, and SuM or SuM→medial septum stimulation evoked arousal and cortical activation during propofol maintenance.
Impact: This mechanistic study identifies a discrete arousal node and projection (SuM→MS) that can reverse anesthetic-induced unconsciousness, offering a circuit-level target to modulate emergence.
Clinical Implications: While preclinical, these results suggest potential neuromodulatory strategies (e.g., targeted stimulation) to hasten emergence, mitigate delayed awakening, and refine depth-of-anesthesia monitoring via circuit biomarkers.
Key Findings
- SuM glutamatergic neuronal activity falls before propofol-induced loss of consciousness and rises at recovery.
- Chemogenetic ablation shortened induction time and prolonged recovery time; activation had opposite effects.
- Optogenetic stimulation of SuM or SuM→medial septum projections induced behavioral arousal and cortical activation during propofol maintenance.
Methodological Strengths
- Multimodal causal tools (fiber photometry, chemogenetics, optogenetics) with projection-specific manipulations
- Quantitative behavioral and cortical readouts under controlled anesthetic conditions
Limitations
- Findings are in mice; translational generalizability to humans is uncertain
- Focused on propofol anesthesia; effects under other anesthetics remain to be tested
Future Directions: Test SuM-targeted neuromodulation across anesthetics and species; identify electrophysiologic biomarkers of SuM engagement predictive of emergence dynamics in humans.
BACKGROUND: Glutamatergic neurons in the supramammillary nucleus (SuM) have previously been shown to be pivotal parts of the wakefulness-sleep regulation system. However, whether they play a role in propofol-mediated modulation of consciousness remains unclear. This study hypothesized that glutamatergic neurons in the SuM contribute to the regulation of altered states of consciousness under propofol anesthesia in mice. METHODS: The effects of propofol anesthesia on neuronal activity were measured by calcium fiber photometry recording. Lesions and chemogenetic activation were used to investigate the role of glutamatergic neurons in the SuM in anesthesia induction, emergence, and sensitivity to propofol. Optogenetic methods were used to further explore the effects of SuM glutamatergic neurons or the projections from the SuM to the medial septum (MS) on cortical activity and behavioral changes during the maintenance of propofol anesthesia. RESULTS: Activities of glutamatergic neurons in the SuM decreased before propofol-induced loss of consciousness and rapidly increased at the onset of consciousness recovery. Chemogenetic ablation of glutamatergic neurons in the SuM reduced the induction time (monomeric Cherry [mCherry] vs. Caspase 3; mean ± SD, 150.1 ± 25.3 s vs. 97.3 ± 22.2 s; P < 0.001; n = 12) and prolonged the recovery time (1,536.0 ± 422.8 s vs. 2,672.0 ± 1,048.0 s; P < 0.001; n = 12) under propofol anesthesia. Chemogenetic activation of glutamatergic neurons in the SuM had opposite effects. Optogenetic stimulation of glutamatergic neurons in the SuM or the neuronal projections from the SuM to the MS induced behavioral arousal and cortical activation during the maintenance of propofol anesthesia. CONCLUSIONS: Glutamatergic neurons in the SuM and their projections to the MS contribute to the regulation of altered states of consciousness under propofol anesthesia in mice.
2. Sensory-selective Peripheral and Neuraxial Nerve Blockade with 2',6'-Pipecoloxylidide.
PPX, a metabolite of amino-amide local anesthetics, produced sensory-only sciatic and intrathecal blocks in rats, with ex vivo recordings indicating preferential Aδ- over C-fiber block. Repeated intrathecal PPX maintained sensory selectivity, and systemic toxicity thresholds were favorable compared with ropivacaine, with benign tissue reactions.
Impact: Demonstrating motor-sparing, sensory-selective block with a favorable safety profile addresses a long-standing need for analgesia that preserves motor function.
Clinical Implications: If translated clinically, PPX-like agents could reduce fall risk and enable early mobilization after regional anesthesia, and may offer safer dosing margins than current amide local anesthetics.
Key Findings
- In rats, 30 mM PPX produced sensory-only sciatic block (~67 min) with no motor block, while 15 mM ropivacaine produced both sensory and motor block (~150 min).
- Intrathecal PPX yielded sensory-only block (~25 min) and maintained selectivity with repeated dosing; permeation enhancers abolished selectivity.
- Ex vivo, 15 mM PPX blocked Aδ fibers but not C fibers; systemic PPX caused no severe clinical toxicity at ~75 mg/kg, unlike ropivacaine.
Methodological Strengths
- Integrated in vivo (peripheral and intrathecal), ex vivo single-unit recordings, and histology for safety/biocompatibility
- Sex-stratified evaluation and direct comparator (ropivacaine) with standardized sensory/motor assays
Limitations
- Preclinical rodent and ex vivo models; human efficacy and dosing remain unknown
- Sensory-selective duration was modest and disrupted by permeation enhancers; female rats required higher concentrations
Future Directions: Phase 1 trials to characterize human safety, sensory-motor selectivity, and pharmacokinetics; formulation work to preserve selectivity while extending duration.
BACKGROUND: Safe sensory-selective local anesthetics would be a major advance in the management of acute and chronic pain. This articles describes the sensory-selective local anesthetic properties and the toxicity profile of a known metabolite of amino-amide local anesthetics, 2',6'-pipecoloxylidide (PPX). METHODS: PPX was synthesized and made into its hydrochloride salt. PPX or ropivacaine (ROP) were injected at the sciatic nerve or intrathecally in rats, who then underwent modified hotplate (sensory) testing and weight-bearing (motor) testing. Rats injected with PPX or ROP were assessed for clinical toxicity endpoints. Conduction blockade was studied with single-unit recordings in mice. Biocompatibility was assessed histologically. RESULTS: In male rats, sciatic sensory and motor block from 15 mM ROP lasted approximately 150 min; sensory nerve block from 30 mM PPX lasted 67.4 ± 17.4 min without motor block. The addition of chemical permeation enhancers to 30 mM PPX abolished sensory selectivity. Intrathecal 15 mM ROP produced sensory and motor block lasting approximately 15 min; sensory block from 30 mM PPX lasted 24.8 ± 8.7 min without motor block; repeated injection caused continuous sensory-selective block. In female rats, sciatic nerve blocks with ROP were similar to blocks in males, while blocks with PPX were sensory-selective, but higher PPX concentrations were required. Ex vivo , 1.5 mM ROP caused reversible block of Aδ and C-fibers; 15 mM PPX blocked Aδ-fibers but not C-fibers. Systemic 39.0 ± 1.8 mg/kg ROP caused severe clinical toxicity; 75.3 ± 3.2 mg/kg PPX caused none. Tissue reaction to PPX was benign, comparable to that of ROP. CONCLUSIONS: PPX provides sensory-selective local and neuraxial anesthesia with a good safety profile. The sensory selectivity may be attributable to the particular hydrophilic-hydrophobic balance of PPX.
3. Posttransfusion recovery, quality, and metabolism of short- and long-term stored platelets during controlled inflammation.
In a registered controlled human endotoxemia study with autologous platelet transfusion, short-stored (2-day) platelets showed metabolomic and surface marker profiles associated with superior posttransfusion recovery during inflammation compared with 7-day stored units. Higher dense granule metabolites and lower CD62P/lactate correlated with improved PTR.
Impact: Provides mechanistically anchored, controlled human evidence that platelet storage duration materially affects recovery during inflammation, informing inventory and transfusion policies in perioperative and critical care.
Clinical Implications: Prefer short-stored platelets for patients with systemic inflammation (e.g., sepsis, major surgery) to maximize PTR; consider integrating metabolomic/surface marker profiles (e.g., CD62P) into quality selection and transfusion decision-making.
Key Findings
- Short-stored PCs had higher glycolysis/PPP activity and dense granule metabolites; long-stored PCs had elevated transsulfuration/taurine metabolism and higher CD62P/CD63.
- During LPS-induced inflammation, PTR decreased, particularly with 7-day stored platelets.
- Higher dense granule components and lower CD62P and lactate correlated with improved PTR, supporting preferential use of short-stored platelets during inflammation.
Methodological Strengths
- Controlled human endotoxemia model with autologous platelet transfusion and trial registration
- Integrative mass spectrometry metabolomics, flow cytometry, and biotin-labeling to track PTR and phenotype
Limitations
- Small sample size (n=24), all male; generalizability to broader patient populations uncertain
- Restricted storage durations (2 vs 7 days); clinical outcomes beyond PTR not assessed
Future Directions: Validate findings in diverse surgical/ICU cohorts with clinical hemostatic outcomes; develop rapid assays for platelet activation markers to guide bedside product selection.
Platelet concentrates (PCs) are frequently used to prevent and treat bleeding in patients. However, their efficacy is reduced during inflammation as well as due to platelet storage lesion, including metabolomic shifts and changes in surface markers of stored PCs. This study aims to identify disparities between short- and long-term stored PCs during controlled inflammation, focusing on distinct metabolic pathways, alterations in surface markers and posttransfusion recovery (PTR). Twenty-four male participants received lipopolysaccharide or saline as control after an autologous transfusion of either short- (2 days) or long-term (7 days) stored PCs. Metabolomics and surface markers of these transfused PCs were assessed before transfusion using mass spectrometry and flow cytometry, respectively. Biotin-labeled platelets were used to assess surface markers after transfusion and determine PTR. Before transfusion, short-term stored PCs demonstrated increased glycolysis, pentose phosphate pathway activity, dense granule components (eg, serotonin, adenosine diphosphate, and epinephrine), and purine, arginine, and tryptophan metabolism. In contrast, long-term stored PCs exhibited elevated transsulfuration and taurine metabolism, along with higher levels of CD62P and CD63. During inflammation, a decreased PTR was found, particularly in long-term stored PCs. Higher expression of dense granule metabolite components and lower CD62P and lactate levels were correlated with improved PTR. Differences in metabolic pathways, surface markers, and PTR were identified between short- and long-term stored PCs in a controlled human experiment, suggesting a preference for the use of short-term stored PCs during inflammation. This trial was registered at the International Clinical Trials Registry Platform (https://trialsearch.who.int/) as #NL-OMON26852.